A Phase 3 interventional study of Trabectedin and tTF-NGR in Soft Tissue Sarcoma, sponsored by Universität Münster. Recruiting at 14 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Universität Münster · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Sarcoma with a site in Germany — 21 open to participants now, 30 under way, 3 of them phase 3. Sarcoma · Germany.
Among the 103 studies in Sarcoma with a site in Germany, this one is the 34th largest by planned enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2021, is one of 17 in phase 3, reaches primary completion later than 27 of the 29 other live ones, and was the 84th registered.
1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.
Browse Sarcoma studies →21 of the 103 studies in Sarcoma with a site in Germany are open now. Recruiting first, the newest first:
Universität Duisburg-Essen · Sites in Germany
Ages 15+
Technical University of Munich · Sites in Germany
Technische Universität Dresden · Sites in Germany
Ages 18+
Novartis Pharmaceuticals · Sites in Germany, United States, Canada and 4 more countries
Ages 18+
Adcendo ApS · Sites in Germany, United States, Belgium and 2 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 44 · Phase 3 19
First in 1995; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 126 is above the median of 41 across 1,255 interventional studies indexed under Sarcoma.
Median enrollment 103 across the 83 interventional studies, 130 across the 19 observational. Of the 69 that completed or were terminated, 21 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 103 have an industry lead sponsor. The 10 most frequent:
Universität Münster is the lead sponsor of 30 studies on the registry; 19 are open to participants now.
Universität Münster has 1 study filed under Sarcoma — fewer than ten, so there is no comparison to draw.
5 of the studies in Sarcoma with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07939139Technical University of MunichShadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor Boards | 2027-01-31 |
| NCT05492682Valo Therapeutics OySTART: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | 2027-04-30 |
| NCT02650401Hoffmann-La RocheStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | 2027-06-30 |
| NCT07148193Technische Universität DresdenQuality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+) | 2027-09 |
| NCT06743958Technical University of MunichPrehabilitation in Childhood Soft Tissue or Bone Sarcomas | 2027-10-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 103 studies in Sarcoma with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this phase III open label, controlled clinical trial patients with unresectable or metastatic soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs and CD13 positivity in central histology (grade >/= 1+) are treated to evaluate whether tTF-NGR in combination with standard trabectedin chemotherapy prolongs progression-free survival (according to iRECIST), as compared with trabectedin alone. Further objectives are to evaluate the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy with respect to the response rate and overall survival as well as to assess the safety profile of tTF-NGR combined with trabectedin. Before the randomized phase III part of the study, there was a safety run-in part. The final dose of tTF-NGR established as safe in this safety run-in part is 0.5 mg/m2 per day for 2 consecutive days following each trabectedin infusion and is used for the randomized (parallel 1:1; Arm 1: standard trabectedin, Arm 2: standard trabectedin plus tTF-NGR) phase III part of this trail. . Further dose modification for tTF-NGR is possible.
Rationale: tTF-NGR targets CD13 present in tumor-associated vasculature and on tumor cells of the majority of STS tissue samples examined; preclinical data on combination of tTF-NGR with anthracyclines and trabectedin; low competition of targeted or immune therapy in soft tissue sarcoma (STS)
Investigational Medicinal Product: Patients will receive a dose of the Investigational Medicinal Product (IMP) tTF-NGR determined to be safe within the safety run-in cohort of the study as 1-hour rate-controlled infusion (port or central venous access, 0.9 % NaCl ad 100 mL) per day for 4 or lower number of consecutive days following each trabectedin cycle (within 1 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday latest 9 am and on the following day, q d 22 x until disease progression or contraindications against further application.
Indication: Unresectable or metastatic STS after failure of anthracycline-containing first line treatment or with contraindications to these drugs; CD13 positivity in central histology (grade >/= 1+)
Primary objective and endpoints: The primary objective of the trial is to evaluate whether tTF-NGR in combination with standard trabectedin chemotherapy given for unresectable or metastatic soft tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs prolongs progression-free survival, as compared with trabectedin alone. The following efficacy endpoint (for the randomized phase III part) will be considered:
- Progression-free survival (PFS) according to iRECIST (Seymour L, Lancet Oncol. 2017) as judged by central radiology in a blinded fashion after end of trial.
Secondary objectives and endpoints: The secondary objective of the trial is to evaluate the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy given for unresectable or metastatic STS after failure of anthracycline-containing first line therapy or with contraindications to these drugs with respect to the response rate and overall survival as well as to assess the safety profile of tTF-NGR combined with trabectedin.
To assess the efficacy, the following measurements will be considered:
Study design: Open label, randomized, controlled study in subjects with metastatic orrefractory soft tissue sarcoma. Approx. 150 patients will be screened, 126 evaluable patients are enrolled and parallel assigned in a 1:1 fashion to one of two different arms, as outlined below. Randomization will be performed using Pocock's minimization method accounting for the stratification factors CD13+ grades 1 and 2 versus CD13+ grade 3, L-sarcomas versus others (non L-sarcomas), and number of chemotherapy regimen before entry on trial: 1 versus >1.
Safety run-in part:
Before the randomized phase III part of the study, there was a safety cohort of a minimum of 6 patients obtaining at least 2 cycles each of the combination outlined in arm 2 (see below) to confirm safety of this combination (1.5 mg/m2 trabectedin plus a starting dose of 3 mg/m2 tTF-NGR). The patients were treated in-house and in sequence. In case of dose-limiting toxicity (DLT) in one patient of this cohort, a dosemodification protocol for tTF-NGR to 2 mg/m2 was carried out, and in case of further tolerability problems in one patient further deescalations in 0.5 mg/m2 steps of tTF-NGR and/or by a reduction of application days were performed. The safety part of the study is completed and the safe starting dose of tTF-NGR for the randomized phase III part of the study is 0.5 mg/m2 given on days 2 and 3. Since 6 patients tolerated >/= 2 cycles of this dose without DLT in the safety run phase, DLTs are expected to occur in \</= 10 % of the patients treated in arm 2 of the randomized part of the trial. The randomized part of the study is open after approval by the DSMB, Ethics Committee and National Competent Authority (PEI).
Randaomzied Phase III part:
ARM 1:
Trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
ARM 2:
Patients will receive standard trabectedin according to arm 1 plus t0.5 mg/m2 tTF-NGR (1-hour ratecontrolled infusion, port central venous access, 0.9 % NaCl ad 100 mL) one days 2 and 3 following each trabectedin cycle (within max 2 hour interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 10 am and on the following day, q d 22 x until disease progression or contraindications against further application. Further dose modification for tTF-NGR is possible (see chapeter 6.1.4 of the protocol).
As the evaluation of the study results is based on an intention-to-treat analysis, all patients after randomization will be part of the efficacy population as evaluated by central iRECIST evaluation after end of study.
Therapy in both arms can be given on an out-patient basis. All patients receive best supportive care (BSC) according to institutional guidelines. Anti-cancer activity (iRECIST modification) will be assessed (clinically and imaging) at week 9 and then every 9 weeks (independent from cycle length or number) until confirmed progression by iRECIST (iCPD). Decision on application of next cycle at week 9 will be clinical. Imaging and clinical based decision will follow. Transfer of pseudonymized imaging pictures (CD, DVD) and imaging results of a patient to the study center has to be performed after each imaging time point.
Safety assessment will be performed on an ongoing basis during study participation, including standard laboratory assessments. The incidence of AEs will be summarized by severity in all patients with at least one study drug intake.
Number of sites, countries and patients: Multicenter, up to 14 active study sites in Germany. 19 patients were treated in the phase II safety part, 126 patients will be randomized in a 1:1 ratio to receive open label Trabectedin (Arm 1) or Trabectedin plus tTF-NGR (Arm 2) in the phase III part.
Target population: Patients (18-75 years) with advanced or metastatic soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs.
ARM 1: Standard chemotherapy with Trabectidin (in-label)
ARM 2: tTF-NGR added to standard Trabectedin
Severity grading: Hematological and chemical laboratory tests, and AEs will be graded based on CTCAE v. 5.0.
Duration of Treatment: Patients will be treated in repeated cycles until definite disease progression (iRECIST; Seymour L, Lancet Oncol. 2017) in the absence of other withdrawal criteria, and as long as neither patient nor investigator requests treatment discontinuation. This defines End of Treatment (EOT).
Tumor assessments: Detailed tumor assessment visits (clinical and laboratory examinations) after start of therapy are performed before treatment start, at week 9 (+/- 1 week), followed by every 9 weeks (+/- 1 week, independent from cycle length or number) thereafter. Post-study treatment (treatment with another anti-cancer agent) is according to investigator´s choice, but is recorded in the eCRF. At iCPD (confirmed at next tumor assessment after iUPD) tumor assessments will end, but time of death will be recorded for estimation of OS. In case EOT is not determined by iCPD, tumor assessments will go on after EOT until iCPD. Survival status will be collected also for patients withdrawn from the study until death. Transfer of pseudonymized imaging pictures (CD, DVD) and imaging results of a patient to the study center has to be performed after each imaging time point.
Statistical analysis: Safety data of the safety run-in part of the study were evaluated using descriptive statistical methods.
In the primary statistical analysis of the randomized phase III part, the primary endpoint progression-free survival (PFS) according to iRECIST as judged by central blinded radiology will be compared between the two randomized treatment groups (Arm 1 versus Arm 2). The primary statistical analysis will include all randomized patients (full analysis set) and will be performed according to the intention-to-treat principle. A stratified log-rank test with stratification according to the randomization will be applied (two-sided significance level 5%, power 80%) that provides confirmatory statistical evidence.
The timing of the study will be event-driven. The primary statistical analysis will be performed at the time when 106 events in terms of PFS have been observed in total across both treatment groups. This required number of events results from the following sample size calculation. Based on the observed PFS in previous trials, PFS is expected to be exponential, and the expected median PFS is 4.6 months in the control arm (Arm 1) and 8 months in the experimental arm (Arm 2). The corresponding expected hazard ratio is HR=0.575. In a 36 months enrolment period with a rate of 3-4 patients per month, 126 patients will be recruited and randomized. The drop-out process after randomization is expected to be exponential with an up to 25% cumulative drop-out rate at month 24 (competing with the survival process). Follow-up after the last randomized patient is planned to be 12 months, after which it is expected that the required number of 106 events in terms of PFS will have occurred.
The statistical analysis of pre-specified secondary endpoints will be performed with descriptive and inferential statistical methods. Prespecified subgroup analyses will be performed with respect to stratification, L-sarcoma vs. others, FNCLCC grade (2 vs. 3), ECOG performance status (ECOG PS 0 vs. PS 1) and previously obtained Lurbinectedin/Trabectedin versus no such previous exposition. Further exploratory analyses will be performed for other relevant treatment variables (e.g. sex, age, number of treatment cycles).
Safety data will be evaluated and summarized descriptively.
Withdrawal and patient replacement criteria: The patient can withdraw consent for participation in the study at any time without disadvantages for further treatment or prejudice by the therapeutic team. The investigator can withdraw a patient if, in his or her clinical judgment, it is in the best interest of the patient or if the patient cannot comply with the protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have histological evidence of high-grade advanced unresectable or metastatic soft tissue sarcoma (grade 2 - 3) according to the FNCLCC grading system. The following tumor types are included:
Tumor types not listed above may be included upon communication with Coordinating Investigator.
The following tumor types will not be included:
Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures
Exclusion Criteria:
NOTE: Outliers of laboratory values can be disregarded and set aside as exclusion criteria by a Coordinating Investigator´s decision. The conditions for the use of trabectedin as specified in the Summary of Product Characteristics are to be followed according to institutional guidelines for standard of care.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
Drug: Trabectedin
Patients will receive standard trabectedin according to arm 1 plus 0.5 mg/m2 f tTF-NGR (1-hour rate-controlled infusion, port or central venous access, 0.9 % NaCl ad 100 mL) on days 2 and 3 following each trabectedin cycle (within max 2 hours interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 10 am and on the following day, q d 22 x until disease progression or contraindications against further application. Further dose modification for tTF-NGR is possible (see chapter 6.1.4 of the protocol).
Drug: Trabectedin · Biological: tTF-NGR
Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
Also known as: Yondelis
Patients will receive standard trabectedin according to arm 1 plus 0.5 mg/m2 f tTF-NGR (1-hour rate-controlled infusion, port or central venous access, 0.9 % NaCl ad 100 mL) on days 2 and 3 following each trabectedin cycle (within max 2 hours interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 10 am and on the following day, q d 22 x until disease progression or contraindications against further application. Further dose modification for tTF-NGR is possible (see chapter 6.1.4 of the protocol).
Efficacy: Prolongation of progression-free survival (PFS) according to iRECIST as judged by central radiology in a blinded fashion after end of trial.
The primary objective of the trial is to evaluate whether tTF-NGR in combination with standard trabectedin chemotherapy given for unresectable or metastatic soft tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs prolongs progression-free survival, as compared with trabectedin alone. The following efficacy endpoint (for the randomized phase III part) will be considered: \- Progression-free survival (PFS) according to iRECIST (Seymour L, Lancet Oncol. 2017) as judged by central radiology in a blinded fashion after end of trial.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (OOR)
To assess the efficacy, the following measurement will be considered: Overall response rate (ORR, consisting of CR and PR)
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (DCR)
To assess the efficacy, the following measurement will be considered: \- Disease control rate (DCR, consisting of CR, PR, and stable disease (SD) for \>18 weeks)
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (mPFS)
To assess the efficacy, the following measurement will be considered: \- Median progression-free survival (mPFS)
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (mOS)
To assess the efficacy, the following measurement will be considered: \- Median overall survival (mOS)
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy (OS)
To assess the efficacy, the following measurement will be considered: \- Overall survival (OS) rate at 12 and 18 months
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (AE)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Adverse Events (AEs) assessment based on CTCAE v.5.0.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Standard laboratory parameters)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- laboratory parameter: Troponin T hs \[ng/l\]
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: Height)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Height \[m\]
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: Weight)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Weight \[kg\]
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: Body surface)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Body surface area \[m2\]
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Vital sign: breathing)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Vital sign: breathing rate by watching and counting \[breaths per minute\]
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Vital sign: consciousness)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Vital sign: consciousness by talking to the patient
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Vital sign: heart rate)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: Vital sign: heart rate by pulse \[beats per minute\]
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Physical examination: ECOG perfomance status)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Physical examination: ECOG perfomance status
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (ECG)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- ECG (rythm, puls rate, Vector, P Wave, PQ time, QRS Complex, R progression from V1 to V6, QT Interval, PQ time, QRS time, T wave)
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (Echocardiography)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Echocardiography (diameters of both atria and left and right cardiac chambers at end-diastolic and end-systolic times \[mm\], ejection fraction \[%\], wall diameters \[mm\])
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (PRO)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- Patient reported outcomes (PRO) by EORTC QLQ C30 questionnaire
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Evaluation of the safety profile of tTF-NGR combined with standard trabectedin chemotherapy (PK)
To assess the safety profile of tTF-NGR combined with trabectedin the following safety endpoint will be considered: \- pharmacokinetics: AUC \[ng\*h/ml\]
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Plan to share: Yes — De-identified participant data for all primary and secondary outcome measurements will be made available within 6 months of study completion
Supporting information: Study protocol
Time frame: within 6 months of study completion
No publications or documents are linked to this record.
Started Oct 2021 (actual). Primary completion is estimated for Dec 2030, 110 months after the start.
Of 24 phase 3 interventional studies under Sarcoma, half reached primary completion within 105 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 155. This study's planned 110 months is close to that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Aug 2026 → Dec 2030 and completion Dec 2026 → Jun 2031.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universität Münster